Literature DB >> 26442699

Systemic Juvenile Idiopathic Arthritis with Amyloidosis: An Uncommon Complication with a Favourable Outcome.

Avinash Sharma1, Anju Gupta2, Suvradeep Mitra3, Ritambhra Nada3, Sagar Bhattad1, Surjit Singh1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26442699     DOI: 10.1007/s12098-015-1913-1

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


× No keyword cloud information.
  5 in total

1.  Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome.

Authors:  J C Packham; M A Hall
Journal:  Rheumatology (Oxford)       Date:  2002-12       Impact factor: 7.580

2.  Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis.

Authors:  Yasuaki Okuda; Kiyoshi Takasugi
Journal:  Arthritis Rheum       Date:  2006-09

3.  Longterm outcome of amyloidosis associated with juvenile idiopathic arthritis.

Authors:  Kai Immonen; Anneli Savolainen; Hannu Kautiainen; Markku Hakala
Journal:  J Rheumatol       Date:  2008-03-15       Impact factor: 4.666

4.  AA amyloidosis associated with systemic-onset juvenile idiopathic arthritis.

Authors:  Abhijeet Saha; Yogiraj Chopra; Jason D Theis; Julie A Vrana; Sanjeev Sethi
Journal:  Am J Kidney Dis       Date:  2013-05-10       Impact factor: 8.860

Review 5.  Renal amyloidosis in children.

Authors:  Yelda Bilginer; Tekin Akpolat; Seza Ozen
Journal:  Pediatr Nephrol       Date:  2011-03-01       Impact factor: 3.714

  5 in total
  1 in total

Review 1.  Successful use of tocilizumab in amyloidosis secondary to systemic juvenile idiopathic arthritis.

Authors:  Ayush Gupta; Narendra Kumar Bagri; Saroj Kumar Tripathy; Adarsh Barwad; Ravi Hari Phulware; Pankaj Hari
Journal:  Rheumatol Int       Date:  2019-07-04       Impact factor: 2.631

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.